Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: To assess potentially elevated cardiovascular risk related to new antihyperglycemic drugs in patients with type 2 diabetes, regulatory agencies require a comprehensive evaluation of the cardiovascular safety profile of new antidiabetic therapies. We assessed cardiovascular outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo in patients with type 2 diabetes who had had a recent acute coronary syndrome. METHODS: We randomly assigned patients with type 2 diabetes and either an acute myocardial infarction or unstable angina requiring hospitalization within the previous 15 to 90 days to receive alogliptin or placebo in addition to existing antihyperglycemic and cardiovascular drug therapy. The study design was a double-blind, noninferiority trial with a prespecified noninferiority margin of 1.3 for the hazard ratio for the primary end point of a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. RESULTS: A total of 5380 patients underwent randomization and were followed for up to 40 months (median, 18 months). A primary end-point event occurred in 305 patients assigned to alogliptin (11.3%) and in 316 patients assigned to placebo (11.8%) (hazard ratio, 0.96; upper boundary of the one-sided repeated confidence interval, 1.16; P<0.001 for noninferiority). Glycated hemoglobin levels were significantly lower with alogliptin than with placebo (mean difference, -0.36 percentage points; P<0.001). Incidences of hypoglycemia, cancer, pancreatitis, and initiation of dialysis were similar with alogliptin and placebo. CONCLUSIONS: Among patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo. (Funded by Takeda Development Center Americas; EXAMINE ClinicalTrials.gov number, NCT00968708.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DPP-4 inhibitors do not have significant GI adverse effects and may be used in early combination with metformin.1038–1043”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1038]
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [20]
In the citing paper
“Pharmaceutical interventions of 1.5 to 3 years duration report HbA1c reductions of 0.2 to 1.0% with DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 agonists (6, 7, 49).”
In the citing paper
“GLP-1 agents, including dipeptidyl peptidase-4 (DPP-4) inhibitor and glucagon-like peptide-1 receptor agonist (GLP-1 Ra), enhance insulin secretion in pancreatic b-cell and showed many benefits in treating diabetes mellitus type 2 but are not a common choice for GDM [117,118].”
From Gestational Diabetes Mellitus—Recent Literature Review (2022) · cites this paper as [117]
In the citing paper
“Evidence that glucose lowering reduces the rates of cardiovascular events and death has not been convincingly shown, 4-6”
From Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (2015) · cites this paper as [5]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Self-citationUniversal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Task Force Members, Thygesen, K., Alpert, J. S., White, H. D., Biomarker Group, Jaffe, A. S., Apple, F. S., Galvani, M., Katus, H. A., Newby, L. K., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm355 · Cited by 2,541
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Cardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Cited by
Items 201–300 of 1,012
The safety of gliptins : updated data in 2018
Scheen, A. J. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1444027 · Cited by 126
“A slight risk of acute pancreatitis has been reported in a metaanalysis of the three CV outcome trials (EXAMINE, SAVOR-TIMI 53, TECOS) compared with placebo.”
BackgroundResultInfluentialNakamura, K., Oe, H., Kihara, H., Shimada, K., Fukuda, S., Watanabe, K., Takagi, T., Yunoki, K., Miyoshi, T., Hirata, K., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0110-2 · Cited by 129
“A recent study revealed that alogliptin, a DPP-4 inhibitor, did not increase the frequency of serious adverse events, including hypoglycemia, cancer, pancreatitis, and initiation of dialysis in patients with type 2 diabetes who had a recent acute coronary syndrome [40].”
BackgroundResultRSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017
Bajaj, S. (2018) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-018-0604-7 · Cited by 125
“Recent studies have reported a higher incidence of heart failure hospitalization with saxagliptin and alogliptin [17, 18].”
BackgroundInfluentialWu, S., Hopper, I., Skiba, M., & Krum, H. (2014) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12075 · Cited by 129
Ross, S., Gerstein, H. C., Eikelboom, J., Anand, S. S., Yusuf, S., & Paré, G. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv083 · Cited by 129
Kleinbongard, P., Bøtker, H. E., Ovize, M., Hausenloy, D. J., & Heusch, G. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14839 · Cited by 135
“…exenatide, a GLP‐1 analogue, limits infarct size in patients with STEMI undergoing primary PCI (Lonborg et al., 2012b; Woo et al., 2013), whereas two other trials failed to show reduction of cardiovascular events with long‐term DPP‐4 inhibitor treatment (Scirica et al., 2013; White et al., 2013).”
ResultDiagnosing and managing diabetes in HIV-infected patients: current concepts
Monroe, A. K., Glesby, M. J., & Brown, T. T. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/ciu779 · Cited by 125
“ies, with one study reporting an increased rate of hospitalization for heart failure [56–58].”
BackgroundChamberlain, J. J., Herman, W. H., Leal, S., Rhinehart, A. S., Shubrook, J. H., Skolnik, N., & Kalyani, R. R. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2937 · Cited by 127
“Cardiovascular outcomes trial data for the DPP-4 inhibitors sitagliptin (12), saxagliptin (13), and alogliptin (14) showed no statistically significant differences in rates of major cardiovascular events between treatment and placebo groups.”
BackgroundFuchigami, A., Shigiyama, F., Kitazawa, T., Okada, Y., Ichijo, T., Higa, M., Hiyoshi, T., Inoue, I., Iso, K., Yoshii, H., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0977-z · Cited by 133
Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus
Keating, G. M. (2014) · Drugs · doi:10.1007/s40265-014-0199-3 · Cited by 126
“It is also noteworthy that in SAVOR-TIMI 53 [153] and EXAMINE [154], there were no significant differences between saxagliptin [153] or alogliptin [154] and placebo recipients in the incidence of pancreatitis [153, 154], pancreatic cancer [153] or cancer”
ResultSitagliptin Use in Patients With Diabetes and Heart Failure
Weir, D. L., McAlister, F. A., Senthilselvan, A., Minhas‐Sandhu, J. K., & Eurich, D. T. (2014) · JACC Heart Failure · doi:10.1016/j.jchf.2014.04.005 · Cited by 122
The potential for renoprotection with incretin-based drugs
Tanaka, T., Higashijima, Y., Wada, T., & Nangaku, M. (2014) · Kidney International · doi:10.1038/ki.2014.236 · Cited by 133
Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes
Herman, M. E., O’Keefe, J. H., Bell, D. S. H., & Schwartz, S. S. (2017) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2017.09.001 · Cited by 130
Personalized type 2 diabetes management: an update on recent advances and recommendations
Williams, D. M., Jones, H., & Stephens, J. W. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s331654 · Cited by 121
DPP-4 Inhibition and the Path to Clinical Proof
Åhrén, B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00376 · Cited by 138
Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
Azoulay, L., Filion, K. B., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Durand, M., Juurlink, D. N., Targownik, L. E., Turin, T. C., et al. (2016) · BMJ · doi:10.1136/bmj.i581 · Cited by 120
Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis
Azoulay, L., Filion, K. B., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Durand, M., Hu, N., Juurlink, D. N., Paterson, J. M., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.1522 · Cited by 120
Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists
Wilcox, T., De Block, C., Schwartzbard, A. Z., & Newman, J. D. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.056 · Cited by 112
Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor
Lapuerta, P., Zambrowicz, B., Strumph, P., & Sands, A. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114563304 · Cited by 119
Vaidya, V., Gangan, N., & Sheehan, J. (2015) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2015.1024661 · Cited by 120
“As a result, newer drugs, such as saxagliptin and alogliptin belonging to the class of dipeptidyl peptidase-4 inhibitors, were recently shown to be CV neutral in separate clinical trials: SAVOR [63] and EXAMINE [64] potentially improving condition and reducing costs in contrast with some antihyperglycemic medications…”
BackgroundLee, M. M. Y., McMurray, J. J. V., Lorenzo-Almorós, A., Kristensen, S. L., Sattar, N. A., Jhund, P. S., & Petrie, M. C. (2018) · Heart · doi:10.1136/heartjnl-2016-310342 · Cited by 131
Diabetic Vasculopathy: Molecular Mechanisms and Clinical Insights
Jia, G., Bai, H., Mather, B., Hill, M. A., Jia, G., & Sowers, J. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020804 · Cited by 135
Kim, S. C., Schneeweiß, S., Glynn, R. J., Doherty, M., Goldfine, A. B., & Solomon, D. H. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-205216 · Cited by 125
Meneilly, G. S., Knip, A., Miller, D. B., Sherifali, D., Tessier, D., & Zahedi, A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.021 · Cited by 150
Patti, G., Cavallari, I., Andreotti, F., Calabrò, P., Cirillo, P. L., Denas, G., Galli, M., Golia, E., Maddaloni, E., Marcucci, R., et al. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0080-2 · Cited by 128
The Treatment of Type 2 Diabetes
Pfeiffer, A. F. H., & Klein, H. H. (2014) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2014.0069 · Cited by 209
Hippisley-Cox, J., & Coupland, C. (2016) · BMJ · doi:10.1136/bmj.i3477 · Cited by 117
The pharmacological management of metabolic syndrome
Rask Larsen, J., Dima, L., Correll, C. U., & Manu, P. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1429910 · Cited by 113
“19) Alogliptin [123] Trial: N = 1 RCT Design: 25 mg Alogliptin vs.”
New insights into insulin action and resistance in the vasculature
Manrique, C. M., Lastra, G., & Sowers, J. R. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12395 · Cited by 132
Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes
Scheen, A. J. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1006625 · Cited by 126
“However, the results of the first two prospective trials with cardiovascular outcomes (SAVOR-TIMI 53 and EXAMINE) showed a similar incidence of major cardiovascular AEs compared to placebo.”
BackgroundMethodResultInfluentialSinha, B., & Ghosal, S. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.02.014 · Cited by 113
Filion, K. B., Lix, L. M., Yu, O. H., Dell’Aniello, S., Douros, A., Shah, B. R., St-Jean, A., Fisher, A., Tremblay, E., Bugden, S. C., et al. (2020) · BMJ · doi:10.1136/bmj.m3342 · Cited by 117
Diabetes and Cardiovascular Disease: an Update
Almourani, R., Chinnakotla, B., Patel, R., Kurukulasuriya, L. R., & Sowers, J. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1239-x · Cited by 114
Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps
Mechanick, J. I., Farkouh, M. E., Newman, J. D., & Garvey, W. T. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.046 · Cited by 113
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
Aroor, A. R., Sowers, J. R., Jia, G., & DeMarco, V. G. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00209.2014 · Cited by 111
Tkáč, I., & Raz, I. (2017) · Diabetes Care · doi:10.2337/dc15-1707 · Cited by 112
“In the EXAMINE study, nonadjudicated AP was observed in 0.44% of patients in the alogliptin arm and in 0.30% patients in the placebo group.”
MethodInfluentialUpdate on Diabetic Kidney Disease (DKD): Focus on Non-Albuminuric DKD and Cardiovascular Risk
Scilletta, S., Marco, M. D., Miano, N., Filippello, A., Mauro, S. D., Scamporrino, A., Musmeci, M., Coppolino, G., Barbagallo, F. D. G., Bosco, G., et al. (2023) · Biomolecules · doi:10.3390/biom13050752 · Cited by 140
Do we know the true mechanism of action of the DPP ‐4 inhibitors?
Andersen, E. S., Deacon, C. F., & Holst, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13018 · Cited by 107
Cardiovascular and heart failure safety profile of vildagliptin: a meta‐analysis of 17 000 patients
McInnes, G., Evans, M., Del Prato, S., Stumvoll, M., Schweizer, A., Lukashevich, V., Shao, Q., & Kothny, W. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12548 · Cited by 107
“Many studies included in the meta-analysis were of short duration, but the average length of treatment of ∼1 year is little different from the median duration of treatment in the SAVOR-TIMI-53 (2.1 years) [11] and EXAMINE trials (18 months) [12].”
BackgroundResultInfluentialGodinho, R., Mega, C., Teixeira-de-Lemos, E., Carvalho, E., Teixeira, F., Fernandes, R., & Reis, F. (2015) · Journal of Diabetes Research · doi:10.1155/2015/806979 · Cited by 109
Gantz, I., Chen, M., Suryawanshi, S., Ntabadde, C., Shah, S., O’Neill, E. A., Engel, S. S., Kaufman, K. D., & Lai, E. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0593-8 · Cited by 108
“0 years, respectively, but was similar to the median follow-up in EXAMINE [5], although the latter study enrolled a different (postACS) population.”
ResultInfluentialSharma, A., Pagidipati, N. J., Califf, R. M., McGuire, D. K., Green, J. B., Demets, D., George, J. T., Gerstein, H. C., Hobbs, T., Holman, R. R., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.041022 · Cited by 110
Penna, C. R. R., Andreadou, I., Aragno, M., Beauloye, C., Bertrand, L., Lazou, A., Falcão‐Pires, I., Bell, R., Zuurbier, C. J., Pagliaro, P., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14993 · Cited by 114
“…of DPP-4 inhibitors have shown that hospitalisation for HF was increased in saxagliptin-treated patients (Scirica et al., 2013), whereas the rates of major adverse cardiovascular events were not increased with the alogliptin and sitagliptin as compared with (Green et al., 2015; White et al., 2013).”
Rizzo, M., Chandalia, M., Patti, A. M., Di Bartolo, V., Rizvi, A. A., Montalto, G., & Abate, N. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-49 · Cited by 107
Raparelli, V., Elharram, M., Moura, C. S., Abrahamowicz, M., Bernatsky, S., Behlouli, H., & Pilote, L. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.012940 · Cited by 106
Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Plosker, G. L. (2014) · Drugs · doi:10.1007/s40265-013-0169-1 · Cited by 117
“Of note is that saxagliptin was associated with a significantly higher rate of hospitalization for heart failure than placebo in patients with type 2 diabetes in the SAVOR-TIMI 53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53) trial [1…”
BackgroundPharmacological Treatment and Current Management of Peripheral Artery Disease
Bonaca, M. P., & Creager, M. A. (2015) · Circulation Research · doi:10.1161/circresaha.114.303505 · Cited by 112
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
Holman, R. R., Bethel, M. A., George, J., Sourij, H., Doran, Z., Keenan, J., Khurmi, N. S., Mentz, R. J., Oulhaj, A., Buse, J. B., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2015.12.009 · Cited by 108
Nishimura, R., Kato, H., Kisanuki, K., Oh, A., Hiroi, S., Onishi, Y., Guelfucci, F., & Shimasaki, Y. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025806 · Cited by 104
Scheen, A. J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.978289 · Cited by 106
“Such statistical difference was not observed in EXAMINE, a randomised controlled trial that compared aloglitin with placebo in a high-risk T2DM population with a recent acute coronary syndrome [134].”
MethodResultInfluentialYildirim, O., Gottwald, M., Schüler, P., & Michel, M. C. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00461 · Cited by 117
“The EXAMINE trial of cardiovascular outcomes in diabetic patients treated with the dipeptidyl peptidase IV inhibitor alogliptin is an example of adapted sample sizes (White et al., 2013).”
BackgroundOu, S.-M., Shih, C.-J., Chao, P.-W., Chu, H., Kuo, S.-C., Lee, Y.-J., Wang, S.-J., Yang, C.-Y., Lin, C.-C., Chen, T.-J., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0308 · Cited by 101
Heart Failure Outcomes in Clinical Trials of Glucose-Lowering Agents in Patients with Diabetes
Fitchett, D. H., Udell, J. A., & Inzucchi, S. E. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.633 · Cited by 102
Entwicklung und Wandel in der Gesundheitspolitik
Wille, E. (2016) · Peter Lang D eBooks · doi:10.3726/978-3-631-69650-7 · Cited by 102
Scheen, A. J. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0198-2 · Cited by 102
“8 %) [74].”
Risk of pancreatitis in patients treated with incretin-based therapies
Meier, J. J., & Nauck, M. A. (2014) · Diabetologia · doi:10.1007/s00125-014-3231-y · Cited by 101
“When the results of the recently published outcome trials with saxagliptin [8] and alogliptin [7] were included in the analysis, the pooled incidence rates were 1.”
BackgroundResultMulvihill, E. E., Varin, E. M., Ussher, J. R., Campbell, J. E., Bang, K. W. A., Abdullah, T., Baggio, L. L., & Drucker, D. J. (2016) · Diabetes · doi:10.2337/db15-1224 · Cited by 101
“Furthermore, patients receiving alogliptin in the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial exhibited a small numeric excess of HF events (10,11).”
Pasternak, B., Wintzell, V., Melbye, M., Eliasson, B., Svensson, A., Franzén, S., Guðbjörnsdóttir, S., Hveem, K., Jonasson, C., Svanström, H., et al. (2020) · BMJ · doi:10.1136/bmj.m1186 · Cited by 113
Goldney, J., Sargeant, J. A., & Davies, M. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05988-3 · Cited by 100
“Although DPP-4is have proven cardiovascular safety [2, 3], only GLP-1RAs have demonstrated a reduction in major adverse cardiac events (MACE) [4, 5].”
Lovshin, J. A., Rajasekeran, H., Lytvyn, Y., Lovblom, L. E., Khan, S., Alemu, R., Locke, A., Lai, V., He, H., Hittle, L., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0061 · Cited by 100
“The cardiovascular safety of DPP-4 inhibition with sitagliptin (5), alogliptin (6), and saxagliptin (7) has been demonstrated in large outcome studies; however, saxagliptin and alogliptin may increase hospitalization for heart failure, particularly in patients with preexisting heart or kidney disease (8).”
Role of Tight Glycemic Control during Acute Coronary Syndrome on CV Outcome in Type 2 Diabetes
Sasso, F. C., Rinaldi, L., Lascar, N., Marrone, A., Pafundi, P. C., Adinolfi, L. E., & Marfella, R. (2018) · Journal of Diabetes Research · doi:10.1155/2018/3106056 · Cited by 98
“In particular, alogliptin was originally used in diabetic patients with either acute myocardial infarction (AMI) or unstable angina requiring hospitalization within the previous 15 to 90 days [15].”
MethodGiugliano, D., Maiorino, M. I., Bellastella, G., Chiodini, P., & Esposito, K. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012356 · Cited by 99
Engler, C., Leo, M., Pfeifer, B. E., Juchum, M., Chen-Koenig, D., Pölzl, K., Schoenherr, H., Vill, D., Oberdanner, J., Eisendle, E., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001279 · Cited by 116
Helmstädter, J., Keppeler, K., Küster, L., Münzel, T., Daiber, A., & Steven, S. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15462 · Cited by 99
“Inhibition of DPP-4 by saxagliptin, alogliptin, or sitagliptin in the clinical trials SAVOR-TIMI 53 (Scirica et al., 2013), EXAMINE (alogliptin trial White et al., 2013) and TECOS (J. B. Green et al., 2015), respectively, did not increase the risk of CV death, MI or stroke in patients suffering…”
BackgroundFudim, M., White, J., Pagidipati, N. J., Lokhnygina, Y., Wainstein, J., Murin, J., Iqbal, N., Öhman, P., Lopes, R. D., Reicher, B., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.041659 · Cited by 99
Future glucose-lowering drugs for type 2 diabetes
Bailey, C. J., Tahrani, A. A., & Barnett, A. H. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00462-3 · Cited by 112
Salvo, F., Moore, N., Arnaud, M., Robinson, P., Raschi, E., De Ponti, F., Bégaud, B., & Pariente, A. (2016) · BMJ · doi:10.1136/bmj.i2231 · Cited by 99
Stromal derived factor 1α: A chemokine that delivers a two-pronged defence of the myocardium
Bromage, D. I., Davidson, S. M., & Yellon, D. M. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.03.009 · Cited by 97
“in the primary endpoint of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke (White et al., 2013).”
BackgroundGourgari, E., Wilhelm, E. E., Hassanzadeh, H., Aroda, V. R., & Shoulson, I. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.08.005 · Cited by 95
Bentley-Lewis, R., Aguilar, D., Riddle, M. C., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Johnston, P., Køber, L. V., Lawson, F., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.02.002 · Cited by 98
Marfella, R., Sardu, C., Balestrieri, M. L., Siniscalchi, M., Minicucci, F., Signoriello, G., Calabrò, P., Mauro, C., Pieretti, G., Coppola, A., et al. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0304-3 · Cited by 97
“GLP-1 levels (Active GLP-1 [7-36] Specific ELISA Kit; Epitope Diagnostics) were measured after an overnight fast (at 8:00 A.”
MethodStatistical Controversies in Reporting of Clinical Trials
Pocock, S., McMurray, J. J. V., & Collier, T. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.023 · Cited by 103
“The 2 subsequent EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) (6) and TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) (7) trials of drugs in the same class, alogliptin and sitagliptin, respectively, revealed no excess of heart failure, and there is no plaus…”
Monami, M., Dicembrini, I., & Mannucci, E. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0892-7 · Cited by 99
Are targeted therapies for diabetic cardiomyopathy on the horizon?
Tate, M., Grieve, D., & Ritchie, R. H. (2017) · Clinical Science · doi:10.1042/cs20160491 · Cited by 104
Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies
Schernthaner, G., & Schernthaner-Reiter, M. H. (2018) · Diabetologia · doi:10.1007/s00125-018-4547-9 · Cited by 101
Heart Failure Around the World
Tromp, J., Ferreira, J. P., Janwanishstaporn, S., Shah, M., Greenberg, B., Zannad, F. M., & Lam, C. S. P. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1585 · Cited by 99
Self-citationThe perils of surrogate endpoints
Weintraub, W. S., Lüscher, T. F., & Pocock, S. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv164 · Cited by 112
Pinto, L. C. F., Rados, D. R. V., Barkan, S. S., Leitão, C. B., & Gross, J. L. (2018) · Scientific Reports · doi:10.1038/s41598-017-19055-6 · Cited by 96
Diabetic cardiomyopathy: Pathophysiology, theories and evidence to date
Athithan, L., Gulsin, G. S., McCann, G. P., & Levelt, E. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i10.490 · Cited by 102
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
Staels, B. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.009 · Cited by 92
Kohsaka, S., Lam, C. S. P., Kim, D. J., Cavender, M. A., Norhammar, A., Jørgensen, M. E., Birkeland, K. I., Holl, R. W., Franch‐Nadal, J., Tangri, N., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30130-3 · Cited by 104
Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome
Harrington, J., Jones, W. S., Udell, J. A., Hannan, K. L., Bhatt, D. L., Anker, S. D., Petrie, M. C., Vedin, O., Butler, J., & Hernandez, A. F. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.02.008 · Cited by 106
Concomitant Diabetes Mellitus and Heart Failure
Dei, A., Fonarow, G. C., Gheorghiade, M., & Butler, J. (2014) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2014.09.002 · Cited by 94
Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
Lim, L.-L., Chow, E., & Chan, J. C. N. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00776-2 · Cited by 91
Emerging treatments for post-transplantation diabetes mellitus
Jenssen, T., & Hartmann, A. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.59 · Cited by 90
Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation
Barale, C., Buracco, S., Cavalot, F., Frascaroli, C., Guerrasio, A., & Russo, I. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-07-0586 · Cited by 86
“• The bioactive native GLP-1(7-36)amide, the GLP-1 analogue Lir-”
BackgroundResultChen, X., He, Z., Zhou, Z., Yang, T., Zhang, X., Yang, Y., Duan, W., & Zhou, S. (2015) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12455 · Cited by 86
“of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE), involving 5380 patients with T2DM and a recent acute coronary syndrome (ACS).(78) The primary end point included a composite of CV death, nonfatal myocardial infarction, or nonfatal stroke.”
MethodCardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis
Savarese, G., Perrone-Filardi, P., D'Amore, C., Vitale, C., Trimarco, B., Pani, L., & Rosano, G. M. C. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.12.017 · Cited by 90
Kloecker, D. E., Davies, M. J., Khunti, K., & Zaccardi, F. (2020) · Annals of Internal Medicine · doi:10.7326/m19-3286 · Cited by 105
Hwangbo, C., Wu, J., Papangeli, I., Adachi, T., Sharma, B., Park, S., Zhao, L., Ju, H., Go, G.-W., Cui, G., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aad4000 · Cited by 87
Management of diabetes in older adults
Sesti, G., Antonelli Incalzi, R., Bonora, E., Consoli, A., Giaccari, A., Maggi, S., Paolisso, G., Purrello, F., Vendemiale, G., & Ferrara, N. (2018) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.11.007 · Cited by 84
“The SAVOR, T ECOS and EXAMINE studies revealed that the incidence of pancreatic cancer did not dif fer between drug and placebo groups [92, 93].”
MethodZhao, H., Wang, L., Wei, R., Xiu, D., Tao, M., Ke, J., Liu, Y., Yang, J., & Hong, T. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12291 · Cited by 88
Eriksson, J. W., Bodegard, J., Nathanson, D., Thuresson, M., Nyström, T., & Norhammar, A. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.055 · Cited by 90
“Hypoglycemia shows a strong association with cardiovascular events, and this could partially explain the reported increased risk of CVD and mortality with sulphonylurea [10,19].”
BackgroundInfluentialDel Prato, S., Camisasca, R., Wilson, C., & Fleck, P. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12377 · Cited by 87
“Definitive findings on risk of MACE with alogliptin, however, are shown in the recent publication of the results of the EXAMINE trial [8].”
BackgroundResultSelf-citationNovel Diabetes Drugs and the Cardiovascular Specialist
Sattar, N. A., Petrie, M. C., Zinman, B., & Januzzi, J. L. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.014 · Cited by 93
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus
Kirkman, M. S., Mahmud, H., & Korytkowski, M. T. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.002 · Cited by 96
Tomović, K., Lazarević, J., Kocic, G. M., Deljanin-Ilić, M., Anderluh, M., & Šmelcerović, A. (2018) · Medicinal Research Reviews · doi:10.1002/med.21513 · Cited by 90
Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury
Zhao, M., Sun, S., Huang, Z., Wang, T., & Tang, H. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11220720 · Cited by 82
GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
Simó, R., & Hernández, C. (2017) · Diabetes · doi:10.2337/db16-1364 · Cited by 86
“In all these studies, the effects of the new drugs on DR were either not reported (7,8,13) or neutral (46,47,51).”
BackgroundDiagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease
Lonardo, A., Ballestri, S., Targher, G., & Loria, P. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.965143 · Cited by 86
Metadata
- Authors
- White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., Cushman, W. C., & Zannad, F.
- Affiliations
- University of Connecticut (US)
- Brigham and Women's Hospital (US)
- University of Sheffield (GB)
- Cleveland Clinic (US)
- Park Nicollet Health Services (US)
- University of Chicago (US)
- Takeda (United States) (US)
- Harvard University (US)
- Memphis VA Medical Center (US)
- Inserm (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-03
- Volume
- 369
- Issue
- 14
- Pages
- 1327-1335
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2127854619
- Cited by
- 2,502
- References
- 23
- Citations by year
- 2026: 43 · 2025: 60 · 2024: 79 · 2023: 107 · 2022: 124 · 2021: 161 · 2020: 225 · 2019: 243 · 2018: 288 · 2017: 279 · 2016: 329 · 2015: 260 · 2014: 248 · 2013: 44
- FWCI
- 231.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0611-10248)
- National Institutes of Health (UL1TR000041)
- Japan Society for the Promotion of Science (24591075)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- alogliptin, DPP-4 inhibitors, type 2 diabetes, acute coronary syndrome, major adverse cardiovascular events, cardiovascular safety, non-inferiority, HbA1c, acute myocardial infarction, unstable angina, hypoglycemia
- MeSH terms
- Aged, Angina, Unstable, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Piperidines, Uracil, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.